Palisade Bio, Inc. (PALI)
NASDAQ: PALI · IEX Real-Time Price · USD
0.399
+0.004 (0.96%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Company Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States.
The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.
It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.
Palisade Bio, Inc.
Country | United States |
Founded | 1996 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 12 |
CEO | J. D. Finley |
Contact Details
Address: 7750 El Camino Real, Suite 5200 Carlsbad, California 92009 United States | |
Phone | (858) 704-4900 |
Website | palisadebio.com |
Stock Details
Ticker Symbol | PALI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001357459 |
CUSIP Number | 696389105 |
ISIN Number | US6963892046 |
Employer ID | 52-2007292 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
J. D. Finley | Chief Executive Officer and Director |
Ryker Willie | Senior Vice President of Finance and Corporate Controller |
Dr. Mitchell Lawrence Jones M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | 8-K | Current Report |
Mar 26, 2024 | 10-K | Annual Report |
Mar 6, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | 8-K | Current Report |
Feb 13, 2024 | D | Notice of Exempt Offering of Securities |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Feb 6, 2024 | DEF 14A | Other definitive proxy statements |